Compass Pathways PLC
NASDAQ:CMPS
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Compass Pathways PLC
Operating Expenses
Compass Pathways PLC
Operating Expenses Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Operating Expenses | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Compass Pathways PLC
NASDAQ:CMPS
|
Operating Expenses
-$179m
|
CAGR 3-Years
-22%
|
CAGR 5-Years
-32%
|
CAGR 10-Years
N/A
|
|
|
Bicycle Therapeutics PLC
NASDAQ:BCYC
|
Operating Expenses
-$320.3m
|
CAGR 3-Years
-35%
|
CAGR 5-Years
-38%
|
CAGR 10-Years
N/A
|
|
|
Immunocore Holdings PLC
NASDAQ:IMCR
|
Operating Expenses
-£440.3m
|
CAGR 3-Years
-34%
|
CAGR 5-Years
-30%
|
CAGR 10-Years
N/A
|
|
|
Genus PLC
LSE:GNS
|
Operating Expenses
-£589m
|
CAGR 3-Years
1%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
-5%
|
|
|
Oxford BioMedica PLC
LSE:OXB
|
Operating Expenses
-£98.4m
|
CAGR 3-Years
7%
|
CAGR 5-Years
-14%
|
CAGR 10-Years
-15%
|
|
|
Niox Group PLC
LSE:NIOX
|
Operating Expenses
-£23m
|
CAGR 3-Years
-4%
|
CAGR 5-Years
7%
|
CAGR 10-Years
11%
|
|
Compass Pathways PLC
Glance View
Compass Pathways Plc functions as an investment holding company. The company is headquartered in Altrincham, Cheshire and currently employs 116 full-time employees. The company went IPO on 2020-09-18. The firm is focused on treatment-resistant depression (TRD). The company is developing COMP360, a psilocybin formulation that includes its pharmaceutical-grade polymorphic crystalline psilocybin, optimized for stability and purity. Its COMP360 psilocybin therapy comprises administration of its COMP360 with psychological support from specially trained therapists with specific professional and educational qualifications. The psilocybin administration session lasts approximately six to eight hours, with patients supported by therapists in a non-directive manner. Psilocybin administration sessions are preceded by preparation sessions, in which patients are given a thorough orientation, and followed by integration sessions to help patients process the range of emotional and physical experiences facilitated by COMP360 administration.
See Also
What is Compass Pathways PLC's Operating Expenses?
Operating Expenses
-179m
USD
Based on the financial report for Dec 31, 2025, Compass Pathways PLC's Operating Expenses amounts to -179m USD.
What is Compass Pathways PLC's Operating Expenses growth rate?
Operating Expenses CAGR 5Y
-32%
Over the last year, the Operating Expenses growth was 0%. The average annual Operating Expenses growth rates for Compass Pathways PLC have been -22% over the past three years , -32% over the past five years .
